An Overview of the Diagnosis and Management of Seborrheic Dermatitis
- PMID: 35967915
- PMCID: PMC9365318
- DOI: 10.2147/CCID.S284671
An Overview of the Diagnosis and Management of Seborrheic Dermatitis
Abstract
Seborrheic dermatitis (SD) is a common chronic inflammatory skin disorder that mostly affects young adults in areas rich in sebaceous glands (scalp, face, and trunk). In adolescents and adults, SD clinical presentation may range from mild patches to diffuse scalp scaling. In infants, it mainly occurs on the scalp as yellowish, scaly patches ("cradle cap"). In adults, several environmental triggers are likely to promote SD development, along with fungal colonization by Malassezia spp., sebaceous gland activity, as well as immunosuppression, endocrine, neurogenic and iatrogenic factors. In children, early occurrence in the first trimester suggests the role of excessive sebaceous gland activity from maternal hormones, along with cutaneous microbiome alterations. The diagnosis of SD is usually clinical, and specific laboratory and/or instrumental investigations are seldom required. Treatment is aimed at modulating sebum production, reducing skin colonization by Malassezia spp., and controlling inflammation. In adults, mild-to-moderate scalp SD forms can be managed with topical antifungals (ketoconazole, ciclopirox, miconazole) or antiinflammatory (mild-to-moderate potency corticosteroids) or keratolytic/humectant (propylene glycol) agents. Recommended topical therapeutic options for mild-to-moderate facial or body areas SD include topical ketoconazole, ciclopirox, clotrimazole, mild-to-moderate potency corticosteroids, lithium succinate/gluconate, and topical calcineurin inihibitors (off-label use). In severe and/or resistant cases, the use of systemic antifungal drugs (terbinafine, itraconazole), as well as UVB phototherapy, may be considered. In children, scant scientific evidence supports the effectiveness and safety of topical drugs, and "cradle cap" is usually successfully managed with baby shampoos enriched with emollient agents and vegetable oils. Alternatively, similarly to adult scalp SD, medical device shampoos with antiinflammatory and antifungal properties, containing piroctone olamine, bisabolol, alyglicera, telmesteine, may be used. Beyond pharmacological treatments, an appropriate cosmetic approach, if correctly prescribed, may improve therapeutic outcomes.
Keywords: cosmetics; diagnosis; seborrheic dermatitis; systemic; therapy; topical.
© 2022 Dall’Oglio et al.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Similar articles
-
Cutaneous fungal microbiome: Malassezia yeasts in seborrheic dermatitis scalp in a randomized, comparative and therapeutic trial.Dermatoendocrinol. 2017 Oct 23;9(1):e1361573. doi: 10.1080/19381980.2017.1361573. eCollection 2017. Dermatoendocrinol. 2017. PMID: 29484095 Free PMC article.
-
Seborrheic Dermatitis: Diagnosis and Treatment.Am Fam Physician. 2025 Aug;112(2):166-173. Am Fam Physician. 2025. PMID: 40834373
-
Topical Non-Pharmacological Treatment for Facial Seborrheic Dermatitis.Dermatol Ther (Heidelb). 2019 Sep;9(3):469-477. doi: 10.1007/s13555-019-00319-0. Epub 2019 Aug 8. Dermatol Ther (Heidelb). 2019. PMID: 31396944 Free PMC article. Review.
-
Role of antifungal agents in the treatment of seborrheic dermatitis.Am J Clin Dermatol. 2004;5(6):417-22. doi: 10.2165/00128071-200405060-00006. Am J Clin Dermatol. 2004. PMID: 15663338 Review.
-
Treatment of seborrheic dermatitis.Am Fam Physician. 2000 May 1;61(9):2703-10, 2713-4. Am Fam Physician. 2000. PMID: 10821151
Cited by
-
More yeast, more problems?: reevaluating the role of Malassezia in seborrheic dermatitis.Arch Dermatol Res. 2024 Mar 12;316(4):100. doi: 10.1007/s00403-024-02830-7. Arch Dermatol Res. 2024. PMID: 38472524 Review.
-
A Cohort Clinical Study on the Efficacy of Topical Salicylic Acid/Piroctone Olamine Dandruff Pre-Gel and Cleanser in Improving Symptoms of Moderate to Severe Seborrheic Dermatitis of the Scalp.J Cosmet Dermatol. 2025 Jan;24(1):e16742. doi: 10.1111/jocd.16742. J Cosmet Dermatol. 2025. PMID: 39778065 Free PMC article.
-
Exosome therapy for chronic severe seborrheic dermatitis: A case report.JAAD Case Rep. 2025 Jun 13;62:86-89. doi: 10.1016/j.jdcr.2025.05.015. eCollection 2025 Aug. JAAD Case Rep. 2025. PMID: 40703388 Free PMC article. No abstract available.
-
When Patient Diversity Informs Formulation: Reimagining Treatment for Seborrheic Dermatitis.Dermatol Ther (Heidelb). 2024 May;14(5):1071-1077. doi: 10.1007/s13555-024-01161-9. Epub 2024 Apr 27. Dermatol Ther (Heidelb). 2024. PMID: 38676839 Free PMC article.
-
Association of seborrheic dermatitis with secondary bacterial infections.Arch Dermatol Res. 2025 Feb 20;317(1):444. doi: 10.1007/s00403-025-03999-1. Arch Dermatol Res. 2025. PMID: 39976705 No abstract available.
References
-
- Micali G, Veraldi S, Kwong CW, Suh DH, eds. Seborrheic Dermatitis. 1st ed. Gurgaoon (India): Macmillan Medical Communication; 2015.
-
- Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies. Clin Dermatol. 2013;31(4):343–351. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous